单克隆抗体
医学
阻塞(统计)
胶质瘤
阻断抗体
免疫检查点
CTLA-4号机组
抗体
免疫系统
PD-L1
免疫学
免疫疗法
癌症研究
T细胞
计算机科学
计算机网络
作者
Johnny Duerinck,Louise Lescrauwaet,Iris Dirven,Jacomi Del’haye,Latoya Stevens,Xenia Geeraerts,Freya Vaeyens,Wietse Geens,Stefanie Brock,Anne‐Marie Vanbinst,Hendrik Everaert,Ben Caljon,Michaël Bruneau,Laetitia Lebrun,Isabelle Salmon,Mark Kockx,Sandra Tuyaerts,Bart Neyns
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2024-10-16
卷期号:26 (12): 2208-2221
被引量:20
标识
DOI:10.1093/neuonc/noae177
摘要
Abstract Background Recurrent high-grade glioma (rHGG) lacks effective life-prolonging treatments and the efficacy of systemic PD-1 and CTLA-4 immune checkpoint inhibitors is limited. The multi-cohort Glitipni phase I trial investigates the safety and feasibility of intraoperative intracerebral (iCer) and postoperative intracavitary (iCav) nivolumab (NIVO) ± ipilimumab (IPI) treatment following maximal safe resection (MSR) in rHGG. Materials and methods Patients received 10 mg IV NIVO within 24 h before surgery, followed by MSR, iCer 5 mg IPI and 10 mg NIVO, and Ommaya catheter placement in the resection cavity. Biweekly postoperative iCav administrations of 1–5–10 mg NIVO (cohort 4) or 10 mg NIVO plus 1–5–10 mg IPI (cohort 7) were combined with 10 mg IV NIVO for 11 cycles. Results 42 rHGG patients underwent MSR with iCer NIVO + IPI. 16 pts were treated in cohort 4 (postoperative iCav NIVO at escalating doses) while 28 patients were treated in cohort 7 (intra and postoperative iCav NIVO and escalating doses of IPI). The most common TRAE was fatigue; no grade 5 AE occurred. Dose-limiting toxicity was grade 3 neutrophilic pleocytosis (4 pts) receiving iCav NIVO plus 5 or 10 mg IPI. PFS and OS did not significantly differ between cohorts (median OS: 42 [95% CI 26–57] vs. 35 [29–40] weeks; 1-year OS rate: 37% vs. 29%). Baseline B7–H3 expression significantly correlated with worse survival. OS compared favorably to a historical pooled cohort (n = 469) of Belgian rHGG pts treated with anti-VEGF therapies (log-rank P = .015). Conclusion Intraoperative iCer IPI + NIVO with postoperative iCav NIVO ± IPI up to biweekly doses of 1 mg IPI + 10 mg NIVO is feasible and safe, showing encouraging OS in rHGG patients. ClinicalTrials.gov registration: NCT03233152
科研通智能强力驱动
Strongly Powered by AbleSci AI